🔎 Trials Near Me

Início › Câncer de Mama › Pensilvânia

Ensaios clínicos de Câncer de Mama em Pensilvânia

93 estudos para Câncer de Mama estão buscando participantes em locais em Pensilvânia.

Cidades em Pensilvânia

Texto oficial do estudo (Inglês)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
  • University of Pittsburgh Medical Center, Pittsburgh
  • WellSpan York Cancer Center, York
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750

Distance-Based Exercise to Preserve Function and Prevent Disability

  • UPMC Hillman Cancer Center at Butler Health System, Butler
  • IRMC Cancer Center, Indiana
  • UPMC Hillman Cancer Center - New Castle, New Castle
  • e mais 2
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07059884

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

  • Consultants In Med Onco And Hema, Drexel Hill
  • Univ of Pittsburg Med Ctr Pinnacle, Harrisburg
  • Allegheny Health Network, Pittsburgh
RecrutandoFase 3
Idades de 18 a 100 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05827081

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

  • Lehigh Valley Health Network (Data Collection Only), Allentown
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05534438

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Geisinger Medical Center, Danville
  • e mais 7
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  • Alliance Cancer Specialists, Horsham
  • University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine, Philadelphia
  • University of Pittsburgh (UPMC), Pittsburgh
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06369285

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Penn State Milton S. Hershey Medical Center, Hershey
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06324357

Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

  • Allegheny General Hospital, Pittsburgh
RecrutandoEstudo observacional
Idades de 20 a 89 · Mulheres · Atualizado em 30 de set. de 2026 · NCT07023887

A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer

  • AHN Allegheny General Hospital, Pittsburgh
  • Allegheny General Hospital, Pittsburgh
Recrutando
Idades de 20 a 89 · Mulheres · Atualizado em 30 de set. de 2026 · NCT07698314

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, Pittsburgh
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT05877599

EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer

  • AHN Allegheny General Hospital, Pittsburgh
  • AHN Allegheny General Hospital, Pittsburgh
Recrutando
Idades de 20 a 89 · Mulheres · Atualizado em 28 de set. de 2026 · NCT07704476

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Philadelphia
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05867251

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  • University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058), Pittsburgh
  • Cancer Care Associates Of York ( Site 0063), York
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07060807

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Recrutando
Idades 30 e acima · Mulheres · Atualizado em 25 de set. de 2026 · NCT02945579

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  • Thomas Jefferson University - Clinical Research Institute ( Site 0056), Philadelphia
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312176

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

  • Penn Medicine - Lancaster General Hospital, Lancaster
  • Capital Health Hematology Oncology Specialists, Newton
  • Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia
  • e mais 2
RecrutandoFase 3
Idades 60 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06377852

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  • Clinical Trial Site, Horsham
  • Clinical Trial Site, Sayre
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • Allegheny (AHN), Pittsburgh
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  • St. Luke's University Health Network, Bethlehem
  • Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
  • University of Pennsylvania Hospital, Philadelphia
  • e mais 3
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07174336

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • University of Pittsburgh Medical Center, Pittsburgh
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • University of Pennsylvania, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213791

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT07340541

Identifying Patterns in the Breath of Individuals With Breast Cancer

  • Weinstein Imaging Associates, Pittsburgh
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 74 · Mulheres · Atualizado em 18 de set. de 2026 · NCT06512350

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  • Lehigh Valley Health Network - Cedar Crest, Allen
  • Consultants In Medical Oncology and Hematology, P.C., Broomall
  • Penn State Milton S. Hershey Medical Center, Hershey
  • e mais 5
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT06492616

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  • Research Site, Pittsburgh
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT05123482

Active Surveillance in Older Women With ER+ Breast Cancer

  • University of Pittsburgh Medical Center, Pittsburgh
RecrutandoEstudo observacional
Idades 70 e acima · Mulheres · Atualizado em 11 de set. de 2026 · NCT07262138

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

  • St. Luke's University Health Network, Bethlehem
  • Guthrie Medical Group, Sayre
RecrutandoFase 1
Idades de 18 a 55 · Mulheres · Atualizado em 9 de set. de 2026 · NCT07310420

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

  • Penn State Health Milton S. Hershey Medical Center, Hershey
  • University of Pennsylvania - Abramson Cancer Center, Philadelphia
  • UPMC - Hillman Cancer Center, Pittsburgh
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT07100106

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

  • University of Pennsylvania, Philadelphia
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT05315700

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

  • Penn State Cancer Institute, Hershey
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT04886531

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07216105

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

  • Abramson Cancer Center, Philadelphia
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT05964504

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Bryn Mawr Hospital, Bryn Mawr
  • e mais 56
RecrutandoFase 3
Idades de 18 a 60 · Mulheres · Atualizado em 2 de set. de 2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • UPMC Hillman Cancer Center, Pittsburgh
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07029399

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
  • UPMC, Pittsburgh
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT06774963

Biennial CEM in Women With a Personal History of Breast Cancer

  • UPMC Magee-Womens Imaging - Bethel Park, Bethel Park
  • UPMC Magee at the Lemieux Sports Complex, Cranberry Township
  • Magee Womancare Monroeville, Monroeville
  • e mais 3
RecrutandoVoluntários saudáveis bem-vindos
Idades de 30 a 79 · Mulheres · Atualizado em 19 de ago. de 2026 · NCT06105749

ATEMPT 2.0: Adjuvant T-DM1 vs TH

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia
  • University of Pittsburgh Medical Center Cancer UPMC- Magee Women's Hospital, Pittsburgh
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT04893109

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT02732171

EXERT-BC Cardio: Cardio or Conditioning Training With Breast Cancer

  • AHN Allegheny General Hospital, Pittsburgh
Recrutando
Idades de 20 a 89 · Mulheres · Atualizado em 17 de ago. de 2026 · NCT07739563

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.